ifosfamide has been researched along with Carcinoma, Transitional Cell in 34 studies
Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
Excerpt | Relevance | Reference |
---|---|---|
" Mesna was administered intravenously at a 20% of the ifosfamide dosage before ifosfamide and orally at 40% after 4 and 8 hours from the ifosfamide infusion." | 6.68 | Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. ( Pensa, F; Pronzato, P; Tani, F; Vaira, F; Vanoli, M; Vigani, A, 1997) |
"The activity of ifosfamide in genitourinary malignancies has been documented in testicular cancer and bladder cancer." | 4.79 | The role of ifosfamide in the treatment of testicular and urothelial malignancies. ( Roth, BJ, 1996) |
"High-dose ifosfamide (HD-IFX) has shown significant antitumor activity in advanced sarcoma and breast carcinoma." | 3.69 | Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis. ( Albanell, J; Baselga, J; Bellmunt, J; Casado, S; Eres, N; Ribas, A, 1997) |
"Ifosfamide (IFX) is an agent as yet unstudied in advanced urothelial carcinoma." | 2.68 | Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. ( Bono, B; Dreicer, R; Elson, P; Knop, R; Loehrer, PJ; Richardson, RR; Witte, RS, 1997) |
" Mesna was administered intravenously at a 20% of the ifosfamide dosage before ifosfamide and orally at 40% after 4 and 8 hours from the ifosfamide infusion." | 2.68 | Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. ( Pensa, F; Pronzato, P; Tani, F; Vaira, F; Vanoli, M; Vigani, A, 1997) |
" The aim of this retrospective study was to evaluate the activity and toxicity of bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer." | 1.40 | Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases. ( Li, Y; Shang, YM; Yang, Y; Zheng, H, 2014) |
"They were 26 bladder cancers and 19 renal cell cancers." | 1.30 | Clinical application of an in vitro chemosensitivity test, the Histoculture Drug Response Assay, to urological cancers: wide distribution of inhibition rates in bladder cancer and renal cell cancer. ( Fujita, K; Hirano, Y; Suzuki, K; Ushiyama, T, 1999) |
" (1) The tumor growth was inhibited by CDGP-II in all three different dosage groups (p < 0." | 1.29 | [Evaluation of the chemotherapy of a transplantable bladder tumour strain (NM-B-1) by two anti-cancer drugs in combination with a pressor agent in nude mice]. ( Akima, S; Horiuchi, K; Tsuboi, N; Yoshida, K, 1995) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (2.94) | 18.7374 |
1990's | 13 (38.24) | 18.2507 |
2000's | 14 (41.18) | 29.6817 |
2010's | 5 (14.71) | 24.3611 |
2020's | 1 (2.94) | 2.80 |
Authors | Studies |
---|---|
Hosomi, T | 1 |
Shibasaki, N | 1 |
Otsuka, H | 1 |
Uketa, S | 1 |
Makino, Y | 1 |
Shichiri, Y | 1 |
Li, Y | 1 |
Yang, Y | 1 |
Shang, YM | 1 |
Zheng, H | 1 |
Gakis, G | 1 |
Morgan, TM | 1 |
Daneshmand, S | 1 |
Keegan, KA | 1 |
Todenhöfer, T | 1 |
Mischinger, J | 1 |
Schubert, T | 1 |
Zaid, HB | 1 |
Hrbacek, J | 1 |
Ali-El-Dein, B | 1 |
Clayman, RH | 1 |
Galland, S | 1 |
Olugbade, K | 1 |
Rink, M | 1 |
Fritsche, HM | 1 |
Burger, M | 1 |
Chang, SS | 1 |
Babjuk, M | 1 |
Thalmann, GN | 1 |
Stenzl, A | 1 |
Efstathiou, JA | 1 |
Kobayashi, K | 1 |
Matsuyama, H | 1 |
Shimizu, K | 1 |
Fujii, N | 1 |
Inoue, R | 1 |
Yamamoto, Y | 1 |
Matsumoto, H | 1 |
Nagao, K | 1 |
Lawson, M | 1 |
Vasilaras, A | 1 |
De Vries, A | 1 |
Mactaggart, P | 1 |
Nicol, D | 1 |
Milowsky, MI | 1 |
Nanus, DM | 1 |
Maluf, FC | 1 |
Mironov, S | 1 |
Shi, W | 1 |
Iasonos, A | 1 |
Riches, J | 1 |
Regazzi, A | 1 |
Bajorin, DF | 5 |
Kitamura, H | 1 |
Taguchi, K | 1 |
Kunishima, Y | 1 |
Yanase, M | 1 |
Takahashi, A | 1 |
Shigyo, M | 1 |
Tanaka, T | 1 |
Mutoh, M | 1 |
Fukuta, F | 1 |
Masumori, N | 1 |
Tsukamoto, T | 2 |
Siefker-Radtke, AO | 1 |
Dinney, CP | 1 |
Shen, Y | 1 |
Williams, DL | 1 |
Kamat, AM | 1 |
Grossman, HB | 1 |
Millikan, RE | 2 |
Gonzalez-Angulo, AM | 1 |
Orzano, JA | 1 |
Davila, E | 1 |
Maezawa, T | 1 |
Yonese, J | 2 |
Ishii, N | 1 |
Fukui, I | 2 |
Antonelli, A | 1 |
Simeone, C | 1 |
Ferrari, V | 1 |
Tardanico, R | 1 |
Cunico, SC | 1 |
Akima, S | 1 |
Yoshida, K | 1 |
Tsuboi, N | 1 |
Horiuchi, K | 1 |
Kattan, J | 1 |
Culine, S | 1 |
Theodore, C | 1 |
Droz, JP | 1 |
Roth, BJ | 3 |
Dreicer, R | 2 |
Propert, KJ | 1 |
Einhorn, LH | 1 |
Loehrer, PJ | 2 |
Witte, RS | 1 |
Elson, P | 1 |
Bono, B | 1 |
Knop, R | 1 |
Richardson, RR | 1 |
Bellmunt, J | 1 |
Eres, N | 1 |
Ribas, A | 1 |
Casado, S | 1 |
Albanell, J | 1 |
Baselga, J | 1 |
Kyriakakis, Z | 1 |
Dimopoulos, MA | 1 |
Kostakopoulos, A | 1 |
Karayiannis, A | 1 |
Sofras, F | 1 |
Zervas, A | 1 |
Giannopoulos, A | 1 |
Dimopoulos, C | 1 |
Pronzato, P | 1 |
Vigani, A | 1 |
Pensa, F | 1 |
Vanoli, M | 1 |
Tani, F | 1 |
Vaira, F | 1 |
Müller, M | 1 |
Heicappell, R | 1 |
Steiner, U | 1 |
Goessl, C | 1 |
Miller, K | 1 |
McCaffrey, JA | 3 |
Hilton, S | 3 |
Mazumdar, M | 3 |
Kelly, WK | 3 |
Scher, HI | 2 |
Spicer, J | 1 |
Herr, H | 3 |
Higgins, G | 2 |
Kitsukawa, S | 1 |
Kinn, T | 1 |
Yoshida, T | 1 |
Izutami, T | 1 |
Ishikawa, Y | 1 |
Sweeney, CJ | 1 |
Williams, SD | 1 |
Finch, DE | 1 |
Bihrle, R | 1 |
Foster, RS | 1 |
Collins, M | 1 |
Fox, S | 1 |
Hirano, Y | 1 |
Ushiyama, T | 1 |
Suzuki, K | 1 |
Fujita, K | 1 |
Dodd, PM | 2 |
Icasiano, E | 2 |
Boyle, MG | 1 |
Edelman, MJ | 1 |
Krege, S | 1 |
Rembrink, V | 1 |
Börgermann, C | 1 |
Otto, T | 1 |
Rübben, H | 1 |
Ivanova, R | 1 |
Veselinova, T | 1 |
Marinov, E | 1 |
Ianev, N | 1 |
Tsvetkov, Ch | 1 |
Gorchev, G | 1 |
von der Maase, H | 1 |
VanderMolen, LA | 1 |
Sheehy, PF | 1 |
Dillman, RO | 1 |
Pagliaro, LC | 1 |
Tu, SM | 1 |
Williams, D | 1 |
Daliani, D | 1 |
Papandreou, CN | 1 |
Logothetis, CJ | 1 |
Yoshimoto, J | 1 |
Nasu, Y | 1 |
Akagi, T | 1 |
Obama, T | 1 |
Tsushima, T | 1 |
Ozaki, Y | 1 |
Matsumura, Y | 1 |
Ohmori, H | 1 |
Asahi, T | 1 |
Ohkita, K | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase I/II Trial of Sequential Doxorubicin/Gemcitabine (AG) and Ifosfamide, Paclitaxel, and Cisplatin (ITP) Chemotherapy (AG-ITP) in Patients With Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium[NCT00003105] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 1997-09-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
5 reviews available for ifosfamide and Carcinoma, Transitional Cell
Article | Year |
---|---|
Urological implications of cyclophosphamide and ifosfamide.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cyclophosphamide; Cystitis; Humans; Ifosfamide; | 2008 |
The role of ifosfamide in the treatment of testicular and urothelial malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Clinical Trials as Top | 1996 |
[Successful multidisciplinary treatment for bladder cancer with priapism. A case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Comb | 1998 |
New approaches to treatment of metastatic bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2000 |
Current and future perspectives in advanced bladder cancer: is there a new standard?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogeni | 2002 |
15 trials available for ifosfamide and Carcinoma, Transitional Cell
Article | Year |
---|---|
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin | 2009 |
Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Disease-F | 2011 |
A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 2013 |
Phase II trial of ifosfamide, fluorouracil, and folinic acid (FIFO regimen) in relapsed and refractory urothelial cancer.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms | 1995 |
Vinblastine, ifosfamide, and gallium nitrate--an active new regimen in patients with advanced carcinoma of the urothelium. A phase II trial of the Eastern Cooperative Oncology Group (E5892).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional | 1997 |
Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Carcinoma, Transitional Cell; Drug Admin | 1997 |
Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic A | 1997 |
Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer.
Topics: Administration, Oral; Aged; Alopecia; Ambulatory Care; Antineoplastic Agents, Alkylating; Bone Marro | 1997 |
Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 1998 |
A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Admi | 1999 |
Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
Topics: Aged; Agranulocytosis; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic | 2000 |
Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 2000 |
Exploring sequenced chemotherapy regimens in the treatment of transitional cell carcinoma of the urothelial tract.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Cyclophosph | 2000 |
Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2001 |
Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; | 2002 |
14 other studies available for ifosfamide and Carcinoma, Transitional Cell
Article | Year |
---|---|
[Advanced Bladder Cancer with Multiple Pulmonary Metastases Treated with Paclitaxel/Ifosfamide/Nedaplatin Therapy : Two Case Reports].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxy | 2023 |
Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2014 |
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Carb | 2015 |
Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 2016 |
Ifosfamide-induced encephalopathy.
Topics: Antineoplastic Agents, Alkylating; Carcinoma, Transitional Cell; Encephalitis; Humans; Ifosfamide; M | 2002 |
[Combination chemotherapy with ifosfamide, 5-fuluorouracil, etoposide and cisplatin for advanced urothelial cancer: the treatment results and significance of tumor marker evaluation in response assessment of chemotherapy].
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 | 2002 |
Durable and complete remission of a metastatic bladder sarcomatoid carcinoma with chemotherapic and surgical treatments.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Carcinoma, Transitional Cell; | 2006 |
[Evaluation of the chemotherapy of a transplantable bladder tumour strain (NM-B-1) by two anti-cancer drugs in combination with a pressor agent in nude mice].
Topics: Angiotensin II; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cel | 1995 |
Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Breast Neoplasms; Carcinoma, Transitional Cell; D | 1997 |
Side effects of chemotherapy for advanced urothelial carcinoma with etoposide and ifosfamide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Etoposide; Femal | 1997 |
Clinical application of an in vitro chemosensitivity test, the Histoculture Drug Response Assay, to urological cancers: wide distribution of inhibition rates in bladder cancer and renal cell cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Drug Resistance; Drug Sc | 1999 |
[Malignant Brenner tumor and transitional cell ovarian carcinoma--description of two cases].
Topics: Antineoplastic Agents; Brenner Tumor; Carcinoma, Transitional Cell; Female; Humans; Ifosfamide; Mesn | 2001 |
Successful treatment of transitional cell carcinoma of the urethra with chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Black People; California; Carcinoma, Transitio | 2002 |
[Combination chemotherapy with cisplatin, ifosfamide and adriamycin in patients with advanced transitional cell carcinoma of the urinary tract].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transiti | 1985 |